<?xml version="1.0" encoding="UTF-8"?>

<rss version="0.91">
<channel>
	<title>Drugs.com - FDA MedWatch Alerts</title>
	<link>https://www.drugs.com/fda_alerts.html</link>
	<description>FDA MedWatch Alerts from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.</description>
	<language>en</language>

	<item>
		<title>Fitoterapia USA Inc. Issues Voluntary Nationwide Recall of Mero Macho Artificial Passion Fruit Flavored Vitamin C Liquid Supplement Due to Presence of Active Ingredient Tadalafil</title>
		<link>https://www.drugs.com/fda/fitoterapia-usa-inc-issues-voluntary-nationwide-recall-mero-macho-artificial-passion-fruit-flavored-14308.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Fitoterapia+USA+Inc.+Issues+Voluntary+Nationwide+Recall+of+Mero+Macho+Artificial+Passion+Fruit+Flavored+Vitamin+C+Liquid+Supplement+Due+to+Presence+of+Active+Ingredient+Tadalafil</link>
		<description>Audience: Consumer Fitoterapia USA Inc., is voluntarily recalling 19,000 bottles of MACHO ARTIFICIAL PASSION FRUIT FLAVORED VITAMIN C LIQUID SUPPLEMENT, liquid dietary supplement to the consumer level. FDA analysis has found the product to be...</description>
		<pubDate>Mon, 16 Sep 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Drug Safety Communication: Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) - Rare but Severe Lung Inflammation</title>
		<link>https://www.drugs.com/fda/safety-communication-ibrance-palbociclib-kisqali-ribociclib-verzenio-abemaciclib-rare-but-severe-14305.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Drug+Safety+Communication%3A+Ibrance+%28palbociclib%29%2C+Kisqali+%28ribociclib%29%2C+and+Verzenio+%28abemaciclib%29+-+Rare+but+Severe+Lung+Inflammation</link>
		<description>Audience: Patient, Health Professional, Oncology September 13, 2019
ISSUE: FDA&amp;nbsp;is warning that Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) used to treat some patients with advanced breast cancers may cause rare but...</description>
		<pubDate>Fri, 13 Sep 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Safety Information: Ranitidine Generics - NDMA Found in Samples of Some Ranitidine Medicines</title>
		<link>https://www.drugs.com/fda/safety-ranitidine-generics-ndma-found-samples-some-ranitidine-medicines-14304.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Safety+Information%3A+Ranitidine+Generics+-+NDMA+Found+in+Samples+of+Some+Ranitidine+Medicines</link>
		<description>Audience: Consumer, Health Professional, Pharmacy September 13, 2019
ISSUE: FDA has learned that some ranitidine medicines, including some products commonly known as the brand-name drug Zantac, contain a nitrosamine impurity called...</description>
		<pubDate>Fri, 13 Sep 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Plastikon Healthcare Issues Voluntary Nationwide Recall of Milk of Magnesia Oral Suspension 2400 mg/30 mL due to Microbial Contamination</title>
		<link>https://www.drugs.com/fda/plastikon-healthcare-issues-voluntary-nationwide-recall-milk-magnesia-oral-suspension-2400-mg-30-ml-14302.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Plastikon+Healthcare+Issues+Voluntary+Nationwide+Recall+of+Milk+of+Magnesia+Oral+Suspension+2400+mg%2F30+mL+due+to+Microbial+Contamination</link>
		<description>Audience: Consumer, Health Professional, Pharmacy September 9, 2019 -- Lawrence, KS, Plastikon Healthcare, LLC is voluntarily recalling Milk of Magnesia 2400 mg/30 mL Oral Suspension, lots 19027D and 19027E, to the patient level. Plastikon...</description>
		<pubDate>Mon, 09 Sep 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Vaping Illnesses: Consumers Can Help Protect Themselves by Avoiding Tetrahydrocannabinol (THC)-Containing Vaping Products</title>
		<link>https://www.drugs.com/fda/vaping-illnesses-consumers-can-help-protect-themselves-avoiding-tetrahydrocannabinol-thc-containing-14299.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Vaping+Illnesses%3A+Consumers+Can+Help+Protect+Themselves+by+Avoiding+Tetrahydrocannabinol+%28THC%29-Containing+Vaping+Products</link>
		<description>Audience: Consumers September 6, 2019 -- Consumers are likely aware of the recent reports of respiratory illnesses -- including some resulting in deaths -- following the use of vaping products. The U.S. Food and Drug Administration (FDA) remains...</description>
		<pubDate>Fri, 06 Sep 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Pacifico National, Inc. dba AmEx Pharmacy Issues Voluntary Nationwide Recall for all Lots of Bevacizumab</title>
		<link>https://www.drugs.com/fda/pacifico-national-inc-dba-amex-pharmacy-issues-voluntary-nationwide-recall-all-lots-bevacizumab-14301.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Pacifico+National%2C+Inc.+dba+AmEx+Pharmacy+Issues+Voluntary+Nationwide+Recall+for+all+Lots+of+Bevacizumab</link>
		<description>Audience: Consumer, Health Professional, Pharmacy August 30, 2019 -- AmEx Pharmacy today announces a voluntary recall of all Lots of Bevacizumab 1.25mg/0.05mL 31G Injectable and all Lots of Bevacizumab 2.5mg/0.1ml Normject TB Injectable that are...</description>
		<pubDate>Fri, 30 Aug 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>FDA Warns About Rare Occurrence of Serious Liver Injury with Use of Hepatitis C Medicines Mavyret, Zepatier, and Vosevi in Some Patients with Advanced Liver Disease</title>
		<link>https://www.drugs.com/fda/fda-warns-rare-occurrence-serious-liver-injury-hepatitis-c-medicines-mavyret-zepatier-vosevi-some-14298.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Warns+About+Rare+Occurrence+of+Serious+Liver+Injury+with+Use+of+Hepatitis+C+Medicines+Mavyret%2C+Zepatier%2C+and+Vosevi+in+Some+Patients+with+Advanced+Liver+Disease</link>
		<description>Audience: Consumer, Health Professional, Pharmacy August 28, 2019 -- The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver...</description>
		<pubDate>Wed, 28 Aug 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>FDA Updates on Angiotensin II Receptor Blocker (ARB) Recalls</title>
		<link>https://www.drugs.com/fda/fda-updates-angiotensin-ii-receptor-blocker-arb-recalls-14201.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Updates+on+Angiotensin+II+Receptor+Blocker+%28ARB%29+Recalls</link>
		<description>Audience: Consumer, Health Professional, Pharmacy 
Investigation ongoing &amp;ndash; This page to be updated as more information is available

IMPORTANT: Medications containing only amlodipine or hydrochlorothiazide (HCTZ) are not being recalled....</description>
		<pubDate>Wed, 28 Aug 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>FDA Review Finds No Increased Risk of Prostate Cancer with Parkinson&apos;s Disease Medicines Containing Entacapone (Comtan, Stalevo)</title>
		<link>https://www.drugs.com/fda/fda-review-finds-no-increased-risk-prostate-cancer-parkinson-s-medicines-containing-entacapone-14296.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Review+Finds+No+Increased+Risk+of+Prostate+Cancer+with+Parkinson%27s+Disease+Medicines+Containing+Entacapone+%28Comtan%2C+Stalevo%29</link>
		<description>Audience: Consumer, Health Professional, Pharmacy August 13, 2019 -- A U.S. Food and Drug Administration (FDA) review of additional data found no increased risk of prostate cancer with the use of entacapone to treat Parkinson&amp;rsquo;s disease. We...</description>
		<pubDate>Tue, 13 Aug 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>FDA Approves Boxed Warning About Increased Risk of Blood Clots and Death with Higher Dose of Tofacitinib (Xeljanz, Xeljanz XR)</title>
		<link>https://www.drugs.com/fda/fda-approves-boxed-warning-increased-risk-blood-clots-death-higher-tofacitinib-xeljanz-xeljanz-xr-14294.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=FDA+Approves+Boxed+Warning+About+Increased+Risk+of+Blood+Clots+and+Death+with+Higher+Dose+of+Tofacitinib+%28Xeljanz%2C+Xeljanz+XR%29</link>
		<description>Audience: Consumer, Health Professional, Pharmacy July 26, 2019 -- The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz...</description>
		<pubDate>Fri, 26 Jul 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Jubilant Cadista Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tablets, USP, Due to Out-of-Specification Dissolution Test Results</title>
		<link>https://www.drugs.com/fda/jubilant-cadista-pharmaceuticals-inc-issues-voluntary-nationwide-recall-drospirenone-ethinyl-14293.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Jubilant+Cadista+Pharmaceuticals+Inc.+Issues+Voluntary+Nationwide+Recall+of+Drospirenone+and+Ethinyl+Estradiol+Tablets%2C+USP%2C+Due+to+Out-of-Specification+Dissolution+Test+Results</link>
		<description>Audience: Consumer, Health Professional, Pharmacy July 23, 2019 -- Salisbury, Maryland, Jubilant Cadista Pharmaceuticals Inc. is voluntarily recalling one lot of Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/ 0.02mg, 28x3 Blister Pack/Carton...</description>
		<pubDate>Tue, 23 Jul 2019 12:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Bayer Statement on Voluntary Recall of Two Lots of Kogenate FS Antihemophilic Factor (Recombinant) in the United States</title>
		<link>https://www.drugs.com/fda/bayer-statement-voluntary-recall-two-lots-kogenate-fs-antihemophilic-factor-recombinant-united-14291.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Bayer+Statement+on+Voluntary+Recall+of+Two+Lots+of+Kogenate+FS+Antihemophilic+Factor+%28Recombinant%29+in+the+United+States</link>
		<description>Audience: Health Professional, Pharmacy Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level. Certain vials from these two lots that were labeled as...</description>
		<pubDate>Fri, 19 Jul 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products Sold by OCuSOFT</title>
		<link>https://www.drugs.com/fda/altaire-pharmaceuticals-inc-issues-voluntary-recall-multiple-ophthalmic-products-sold-ocusoft-14289.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Altaire+Pharmaceuticals%2C+Inc.+Issues+Voluntary+Recall+of+Multiple+Ophthalmic+Products+Sold+by+OCuSOFT</link>
		<description>Audience: Consumer, Health Professional, Pharmacy July 16, 2019 -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the Prescription (RX) and Over-the-Counter (OTC) drug products and lots, within expiry, sold by...</description>
		<pubDate>Tue, 16 Jul 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products Manufactured and Distributed as Altaire Labeled Products</title>
		<link>https://www.drugs.com/fda/altaire-pharmaceuticals-inc-issues-voluntary-recall-multiple-ophthalmic-products-manufactured-14287.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Altaire+Pharmaceuticals%2C+Inc.+Issues+Voluntary+Recall+of+Multiple+Ophthalmic+Products+Manufactured+and+Distributed+as+Altaire+Labeled+Products</link>
		<description>Audience: Consumer, Health Professional, Pharmacy July 15, 2019 -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the over the counter (OTC) and prescription (Rx) drug products and lots, within expiry, it has...</description>
		<pubDate>Mon, 15 Jul 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Altaire Pharmaceuticals, Inc. Issues Voluntary Recall Of Multiple Ophthalmic Products Sold At CVS</title>
		<link>https://www.drugs.com/fda/altaire-pharmaceuticals-inc-issues-voluntary-recall-multiple-ophthalmic-products-sold-cvs-14286.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Altaire+Pharmaceuticals%2C+Inc.+Issues+Voluntary+Recall+Of+Multiple+Ophthalmic+Products+Sold+At+CVS</link>
		<description>Audience: Consumer, Health Professional, Pharmacy July 10, 2019 -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the Over-the-Counter (OTC) drug products and lots, within expiry, sold at CVS Health the during the...</description>
		<pubDate>Wed, 10 Jul 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products Sold at Wal Mart</title>
		<link>https://www.drugs.com/fda/altaire-pharmaceuticals-inc-issues-voluntary-recall-multiple-ophthalmic-products-sold-wal-mart-14284.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Altaire+Pharmaceuticals%2C+Inc.+Issues+Voluntary+Recall+of+Multiple+Ophthalmic+Products+Sold+at+Wal+Mart</link>
		<description>Audience: Consumer, Health Professional, Pharmacy July 5, 2019 -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the Over-the-Counter (OTC) drug products and lots, within expiry, sold at Wal-Mart during the time...</description>
		<pubDate>Fri, 05 Jul 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products</title>
		<link>https://www.drugs.com/fda/altaire-pharmaceuticals-inc-issues-voluntary-recall-multiple-ophthalmic-products-14283.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Altaire+Pharmaceuticals%2C+Inc.+Issues+Voluntary+Recall+of+Multiple+Ophthalmic+Products</link>
		<description>Audience: Consumer, Health Professional, Pharmacy July 3, 2019 -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the prescription drug products and lots, within expiry, distributed during the time period as indicated...</description>
		<pubDate>Wed, 03 Jul 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>PharMEDium Services, LLC Issues Voluntary Nationwide Recall of 0.5 mg/mL HYDROmorphone HCl in 0.9% Sodium Chloride 1 mL in 3 mL BD Syringe Due to Presence of Sulfite</title>
		<link>https://www.drugs.com/fda/pharmedium-services-llc-issues-voluntary-nationwide-recall-0-5-mg-ml-hydromorphone-hcl-0-9-sodium-14281.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=PharMEDium+Services%2C+LLC+Issues+Voluntary+Nationwide+Recall+of+0.5+mg%2FmL+HYDROmorphone+HCl+in+0.9%25+Sodium+Chloride+1+mL+in+3+mL+BD+Syringe+Due+to+Presence+of+Sulfite</link>
		<description>Audience: Consumer, Health Professional, Pharmacy June 28, 2019 -- PharMEDium Services, LLC is voluntarily recalling 45 lots of 0.5 mg/mL HYDROmorphone HCl in 0.9% Sodium Chloride 1 mL in 3 mL BD Syringe to the user level. The product is being...</description>
		<pubDate>Fri, 28 Jun 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>APS Biogroup Recalls Viralox, DPS Throat Spray, Immulox, and Immuno PRP Spray, Because of Possible Health Risk</title>
		<link>https://www.drugs.com/fda/aps-biogroup-recalls-viralox-dps-throat-immulox-immuno-prp-because-possible-health-risk-14276.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=APS+Biogroup+Recalls+Viralox%2C+DPS+Throat+Spray%2C+Immulox%2C+and+Immuno+PRP+Spray%2C+Because+of+Possible+Health+Risk</link>
		<description>Audience: Consumer, Health Professional, Pharmacy June 13, 2019 -- APS BioGroup, Inc., of Phoenix, Arizona is recalling the following products:



	
		
			Product Name
			UPC #
			Expiration Date
		
	
	
		
			Sovereign Laboratories...</description>
		<pubDate>Thu, 13 Jun 2019 00:00:00 GMT</pubDate>
	</item>

	<item>
		<title>Teva Pharmaceuticals USA, Inc. Expands Voluntary Nationwide Recall of Losartan Potassium to 50 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply, Inc.</title>
		<link>https://www.drugs.com/fda/teva-pharmaceuticals-usa-inc-expands-voluntary-nationwide-recall-losartan-potassium-50-mg-100-mg-14275.html?utm_source=ddc&amp;utm_medium=rss&amp;utm_campaign=Teva+Pharmaceuticals+USA%2C+Inc.+Expands+Voluntary+Nationwide+Recall+of+Losartan+Potassium+to+50+mg+and+100+mg+Tablets+USP%2C+Sold+Exclusively+to+Golden+State+Medical+Supply%2C+Inc.</link>
		<description>Audience: Consumer, Health Professional, Pharmacy June 11, 2019 -- Teva Pharmaceuticals USA, Inc. has expanded its voluntary consumer-level recall originally initiated on April 25, 2019 in the United States of losartan potassium tablets. This...</description>
		<pubDate>Tue, 11 Jun 2019 00:00:00 GMT</pubDate>
	</item>
</channel>
</rss>